Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
Launched by NOVARTIS VACCINES · Jul 27, 2011
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female children 2 months to 5 years of age scheduled to receive vaccination
- Exclusion Criteria:
- • Contraindications to Vaxem™Hib Korean Prescribing information
About Novartis Vaccines
Novartis Vaccines, a division of Novartis, is dedicated to the research, development, and commercialization of innovative vaccines aimed at preventing infectious diseases and addressing unmet medical needs globally. With a strong focus on scientific excellence and patient safety, Novartis Vaccines leverages advanced technologies and collaborative partnerships to enhance vaccine efficacy and accessibility. The division is committed to advancing public health through rigorous clinical trials and is driven by a mission to protect lives and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gyeonggi Do, , Korea, Republic Of
Incheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials